The previous study reported no significant survival difference between PD‐1 inhibitors and PD‐L1 inhibitors between various regimens (pembrolizumab, durvalumab, atezolizumab) for overall ES‐SCLC patients in first‐line treatment42; therefore, we merged their data when conducting NMA. Here, PDCD1 is linked to small cell lung carcinoma.